{"nctId":"NCT03085680","briefTitle":"Curcumin and Function in Older Adults","startDateStruct":{"date":"2017-08-11","type":"ACTUAL"},"conditions":["Older Adults","Physical Function","Cognitive Function"],"count":17,"armGroups":[{"label":"Curcumin","type":"EXPERIMENTAL","interventionNames":["Drug: Curcumin"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: microcrystalline cellulose"]}],"interventions":[{"name":"Curcumin","otherNames":["Turmeric","C3 Complex"]},{"name":"microcrystalline cellulose","otherNames":["placebo"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Age \\> 65 years\n* Usual walking speed \\<1 m/sec and \\>0.44 m/sec on the 4 m walk\n* Sedentary lifestyle (\\< 120 min per week of moderate intensity physical activity);\n* CRP \\> 1.0 mg/dL\n* Willingness and ability to give informed consent\n* Willingness to be randomized to the intervention groups\n* Availability for participation through duration of study\n\nExclusion Criteria:\n\nExclusion Criteria (General)\n\n* Unable to complete 400 meter walk test\n* Failure or inability to provide informed consent\n* Residence in a Skilled Nursing Facility (SNF); residence in an Assisted Living Facility (ALF) or independent housing is allowed\n* Self-reported inability to walk one block\n* Blood pressure readings \\>160/100\n* Significant cognitive impairment, defined as a known diagnosis of dementia, or a Mini-Mental State Exam (MMSE) score \\<24\n* Unable to communicate because of severe hearing loss or speech disorder\n* Clinically significant depression (CES-D score \\> 20)\n* Severe cardiac disease, including NYHA Class III or IV congestive heart failure, clinically significant aortic stenosis, history of cardiac arrest, use of a cardiac defibrillator, or uncontrolled angina\n* Severe pulmonary disease, pneumonitis or interstitial lung disease\n* Severe rheumatologic or orthopedic diseases (e.g., awaiting joint replacement, active inflammatory disease)\n* Neurological conditions that cause impaired muscle function or mobility (e.g., Parkinson's Disease, multiple sclerosis, ALS)\n* Other significant co-morbid medical disease (e.g. renal failure with eGFR \\< 30 ml/minute or on hemodialysis) or severe psychiatric disorder (e.g. bipolar, schizophrenia)\n* Terminal illness with life expectancy less than 12 months, as determined by a physician\n* Excessive alcohol use, defined as more than 5 drinks/day for males or more than 4 drinks/day for females, or more than 14 drinks per week\n* Current smoker or less than 3 years smoking cessation\n* Participating in another clinical trial or receiving an investigational product within 3 months prior to screening/enrollment\n\nExclusion Criteria (Curcumin-related)\n\n* Diabetes mellitus currently taking medications to lower blood glucose (oral or by injection)\n* Current use of anticoagulant or anti-platelet medications (aspirin 81 mg daily is allowed)\n* Congenital or acquired bleeding disorders\n* Cholelithiasis or other gall bladder or biliary tract disease\n* Chronic gastrointestinal blood loss or iron deficiency (serum ferritin \\< 12 ng/mL, with or without anemia)\n* History of estrogen-sensitive conditions including breast, uterine, and ovarian cancers; endometriosis; and uterine fibroids\n* History of Tuberculosis (TB), HIV, Hepatitis B or C, or other disease potentially compromising immune function\n* Current use of medications targeting immune or inflammatory function (e.g., sulfasalazine)\n* Current use of anabolic medications (i.e., growth hormones or testosterone), antidepressant medications and antipsychotic agents (including monoamine oxidase inhibitors), or anticholinesterase inhibitors (i.e., Aricept)\n\nTemporary Exclusion Criteria\n\n* Acute infection (urinary, respiratory, other) or hospitalization within 1 month\n* Myocardial infarction, CABG, or valve replacement within past 6 months\n* Pulmonary embolism or deep venous thrombosis within past 6 months\n* Stroke, hip fracture, hip or knee replacement, or spinal surgery within past 4 months\n* Receiving physical therapy for gait, balance, or other lower extremity training","healthyVolunteers":true,"sex":"ALL","minimumAge":"65 Years","maximumAge":"99 Years","stdAges":["OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Curcumin and Physical Function -Walking","description":"To examine the effects of dietary supplementation with curcumin on changes in physical function walking speed- 400meter walk test.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.014","spread":"0.090"},{"groupId":"OG001","value":"0.103","spread":"0.10"}]}]}]},{"type":"PRIMARY","title":"Curcumin and Physical Function - Hand Grip","description":"To examine the effects of dietary supplementation with curcumin on changes in physical function grip strength- hand dynamometer","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.63","spread":"4.90"},{"groupId":"OG001","value":"-0.25","spread":"3.14"}]}]}]},{"type":"SECONDARY","title":"Curcumin and Cognitive Function - Attention & Memory","description":"To examine the effects of dietary supplementation with curcumin on cognitive performance mini-mental state examination. 30 points max. The lower, the worse score.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.33","spread":"3.94"},{"groupId":"OG001","value":"-2.75","spread":"5.09"}]}]}]},{"type":"SECONDARY","title":"Curcumin and Pain","description":"To examine the effects of dietary supplementation with curcumin on pain symptoms (pain scale 0-10 with 10 being the worst)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.97","spread":"1.3"},{"groupId":"OG001","value":"1.3","spread":"1.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"0.4"},{"groupId":"OG001","value":"1.6","spread":"1.7"}]}]}]},{"type":"SECONDARY","title":"Curcumin and Inflammation - Interleukin-6","description":"To examine the effects of dietary supplementation with curcumin on markers of systemic inflammation Interleukin-6 (ng/ml)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.1","spread":"1.4"},{"groupId":"OG001","value":"2.7","spread":"1.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.4","spread":"1.5"},{"groupId":"OG001","value":"3.6","spread":"1.5"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":9},"commonTop":[]}}}